Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by SWS Partners

SWS Partners reduced its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 33.8% in the 3rd quarter, Holdings Channel.com reports. The fund owned 2,240 shares of the medical equipment provider’s stock after selling 1,142 shares during the quarter. SWS Partners’ holdings in Intuitive Surgical were worth $1,100,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after purchasing an additional 493,126 shares during the last quarter. Capital World Investors raised its stake in shares of Intuitive Surgical by 1.0% during the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after purchasing an additional 73,634 shares during the last quarter. Jennison Associates LLC raised its position in Intuitive Surgical by 4.6% in the first quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock worth $1,791,253,000 after acquiring an additional 198,483 shares in the last quarter. American Century Companies Inc. raised its position in Intuitive Surgical by 3.0% in the second quarter. American Century Companies Inc. now owns 2,398,193 shares of the medical equipment provider’s stock worth $1,066,837,000 after acquiring an additional 70,556 shares in the last quarter. Finally, Clearbridge Investments LLC raised its position in Intuitive Surgical by 1.6% in the second quarter. Clearbridge Investments LLC now owns 1,981,297 shares of the medical equipment provider’s stock worth $881,380,000 after acquiring an additional 30,449 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded down $9.85 during mid-day trading on Tuesday, reaching $477.76. The company’s stock had a trading volume of 681,906 shares, compared to its average volume of 1,462,242. The company’s fifty day simple moving average is $481.33 and its two-hundred day simple moving average is $435.81. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $496.48. The stock has a market cap of $169.46 billion, a P/E ratio of 88.02, a P/E/G ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period last year, the business posted $1.18 EPS. Sell-side analysts expect that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now directly owns 3,001 shares in the company, valued at approximately $1,461,006.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the sale, the insider now owns 295 shares in the company, valued at approximately $145,113.45. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock worth $25,528,753 in the last three months. 0.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ISRG shares. Evercore ISI increased their price objective on Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. BTIG Research increased their price objective on Intuitive Surgical from $494.00 to $518.00 and gave the stock a “buy” rating in a research report on Monday. Piper Sandler increased their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their target price for the company from $380.00 to $510.00 in a report on Friday, August 2nd. Finally, Barclays upped their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a report on Thursday, July 18th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $467.55.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.